Riskpilot← Back to searchSign inGet full accessMEDLYTIC AS
ASActiveOrg 921244517Bygdøy Allé 125B, 0273 OsloOther information technology and computer service activities · NACE 6290Est. 20185 employeesmedlytic.no
Revenue 2024
NOK 650K
-54% vs 2023
EBITDA margin
-469.6%
-1133% vs 2023
Equity ratio
65.1%
Financial strength
Net profit 2024
NOK -2,9M
-1420% vs 2023
| Revenue | NOK 650K | -54% |
| EBITDA | NOK -3,1M | -1133% |
| Net profit | NOK -2,9M | -1420% |
| Total assets | NOK 919K | -79% |
| Equity | NOK 598K | -83% |
| Employees | 5 | — |
Legal name
MEDLYTIC AS
Org number
921244517
Legal form
Aksjeselskap
NACE code
6290 · Other information technology and computer service activities
Founded
15. august 2018
Share capital
NOK 30 000
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Daglig leder alene.
Company purpose
Kommersialisere dataprogramvare for prosjekt- og virksomhetsstyring, samt dataanalyse, dataprogrammer for prosjektledelse og databehandling. Hente innsikt fra brukere gjennom fysiske og digitale plattformer, samt deltakelse i andre virksomheter, deriblant deltagelse og investering i annen virksomhet og andre selskaper i inn- og utland. Annen virksomhet som støtter inn under det overnevnte.
Address
Bygdøy Allé 125B, 0273 Oslo
Phone
+4741460919
Website
medlytic.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 518 | 1 433 | 1 423 | 650 |
| Staff expenses | −2 | −324 | −638 | −1 462 | −2 575 |
| EBITDA | −9 | 1 | 6 | −247 | −3 051 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −9 | 1 | 6 | −247 | −3 051 |
| Net financials | 0 | −0 | −0 | 55 | 116 |
| Profit before tax | −9 | 1 | 5 | −193 | −2 936 |
| Tax | −2 | 2 | −1 | 1 | −0 |
| Net profit | −7 | −1 | 6 | −193 | −2 936 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 105 | 280 | 888 | 4 435 | 919 |
| Equity | 22 | 21 | 27 | 3 534 | 598 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 82 | 259 | 861 | 901 | 321 |
| Total debt | 82 | 259 | 861 | 901 | 321 |
EBITDA margin
-469.6%
This company
15.8%
Market median
-3072% vs market
20202024
Equity ratio
65.1%
This company
38.2%
Market median
+70% vs market
20202024
Return on equity
-490.5%
This company
18.4%
Market median
-2766% vs market
20202024
Net profit margin
-451.8%
This company
8.1%
Market median
-5678% vs market
20202024
Asset turnover
0.71×
This company
1.12×
Market median
-37% vs market
20202024
Debt / equity
0.54×
This company
0.62×
Market median
+13% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
RG Chief Executive Officer | Chief Executive Officer | 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2019 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 50% | 50% | 2023 | |
| Company | 50% | 50% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Doktor Innovasjon As
MEDLYTIC AS Board members of MEDLYTIC AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Robert Grinde | Chief Executive Officer | 0 companies |
| Ida Susanna Fattah | Chairman | 0 companies |